Anti-Mouse RGMb Antibody (307.9D1)
Anti-Mouse RGMb Antibody (307.9D1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse RGMb. Anti-Mouse RGMb Antibody (307.9D1) blocks RGMb binding to PD-L2. Anti-Mouse RGMb Antibody (307.9D1) can be used for the researches of cancer inflammation and immunology, such as acute myeloid leukemia (AML) and graft versus-host disease (GVHD).
For research use only. We do not sell to patients.
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
RGMb
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse RGMb Antibody (307.9D1) (450 μg before induction and 200 μg at 2 days after induction, i.p.) inhibits the development of respiratory tolerance and increases T cell proliferation and IL-4 production in ovalbumin-induced respiratory tolerance mice models[2].
Anti-Mouse RGMb Antibody (307.9D1) (200 μg, i.p., every 3 days for 6 times) modestly delays the onset of leukemia and mildly improves survival companied with anti-PD1 and anti-TIM3 in acute myeloid leukemia mice models[3].
Anti-Mouse RGMb Antibody (307.9D1) (20 mg/kg, i.p., at days -1, 3 and 7) inhibits graft versus-host disease with improved survival in NSG mice[4].
Anti-Mouse RGMb Antibody (307.9D1) (200 μg/mouse, i.p., at days -1, 3 and 7) protects mice against weight loss and death in Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis mice models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MC38 tumor mice models[1]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, at days 7, 10, 13, 16 post tumor implantation companied with anti-PD-1 or anti-PD-L1
-
Result:Attenuated tumor growth.
Increased CD8+ and CD4+ T cells and the CD8+ to Treg cell ratio.
Significantly increased TNF-α production by CD4+ T cells.
-
Animal Model:Ovalbumin-induced respiratory tolerance mice models[2]
-
Dosage:450 μg before induction and 200 μg at 2 days after induction
-
Administration:Intraperitoneally injection
-
Result:Developed severe AHR upon rechallenge with OVA.
Had fewer OVA-responsive T cells.
Impaired T cell expansion to antigen.
Reduced the initial expansion of antigen-specific T cells.
-
Animal Model:Mice were injected with murine syngeneic DC/AML fusion cells[3]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, every 3 days for 6 times companied with anti-PD1 and anti-TIM3
-
Result:Modestly delayed the onset of demonstrable leukemia with mildly improved survival.
-
Animal Model:Mice were injected with human PMBC to create graft versus-host disease (GVHD)[4]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneally injection, at days -1, 3 and 7
-
Result:Markedly decreased immune destruction of small and large intestinal villi and ameliorated the GVHD histology score.
Decreased frequency of CD3+ T cells and IL-5, 17, 13, GM-CSF and IFN-γ.
Gene ID
Accession
Q7TQ33 / NP_848730.2
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo RGMb blockade; ELISA; Flow cytometry
Chemical Information
-
Molecular Weight 150 kDa
-
SMILES
[Anti-Mouse RGMb Antibody (307.9D1)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Park JS, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 May;617(7960):377-385. [Content Brief]
[2]. Xiao Y, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014 May 5;211(5):943-59. [Content Brief]
[3]. Stroopinsky D, et al. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 May 1;106(5):1330-1342. [Content Brief]
[4]. Pérez-Cruz M, et al. Immunoregulatory effects of RGMb in gut inflammation. Front Immunol. 2022 Nov 7;13:960329. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse RGMb Antibody (307.9D1) Related Classifications
HY-P990164 Related Classifications
Powered by Bioz